All In Biotech

Drug Trial Radar · NCT05395780

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

An Open-label, Multi-center Phase II Clinical Study on MAX-40279-01 as Second or Later Lines of Treatment of Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Last checked: Nov 19, 2026Latest source record: Jun 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 2022

Primary completion

Dec 2022

Study completion Dec 2023

Sponsor

Lead sponsor
Maxinovel Pty., Ltd.Industry
Sponsor type
Industry
First posted
May 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer

Interventions

  • MAX-40279Drug

    MAX-40279 capsule will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital of Nanjing University Medical School

    Nanjing, Jingsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.